The pentose phosphate pathway is an alternative route for glucose metabolism that generates NADPH for reductive biosynthesis and ribose-5-phosphate for nucleotide synthesis. It operates in the cytoplasm and is particularly active in tissues with high rates of fatty acid or steroid synthesis, such as the liver, adipose tissue, and the adrenal cortex.
Overview and Location
The pathway consists of two distinct phases: an oxidative phase that generates NADPH and ribulose-5-phosphate, and a non-oxidative phase that interconverts sugar phosphates. Unlike glycolysis, the pentose phosphate pathway does not produce ATP, and its primary products are NADPH and ribose-5-phosphate.
Oxidative Phase
The oxidative phase is irreversible and involves three sequential reactions. Glucose-6-phosphate dehydrogenase catalyzes the first committed step, oxidizing glucose-6-phosphate to 6-phosphoglucono-delta-lactone while reducing NADP+ to NADPH. This is the rate-limiting enzyme of the pathway and is tightly regulated by the NADPH-to-NADP+ ratio. Lactonase then hydrolyzes the lactone to 6-phosphogluconate, which is oxidatively decarboxylated by 6-phosphogluconate dehydrogenase to produce ribulose-5-phosphate and a second molecule of NADPH and CO2.
Non-Oxidative Phase
The non-oxidative phase is reversible and connects the pentose phosphate pathway to glycolysis. Ribulose-5-phosphate is isomerized to ribose-5-phosphate by ribulose-5-phosphate isomerase or epimerized to xylulose-5-phosphate by ribulose-5-phosphate epimerase.
A series of transketolase and transaldolase reactions interconvert pentose phosphates with glycolytic intermediates. Transketolase transfers two-carbon units and requires thiamine pyrophosphate as a cofactor. Transaldolase transfers three-carbon units. These enzymes can produce fructose-6-phosphate and glyceraldehyde-3-phosphate from pentose phosphates, allowing the pathway to feed into glycolysis when the demand for NADPH exceeds that for ribose-5-phosphate.
Regulation
The pathway is primarily regulated by the activity of glucose-6-phosphate dehydrogenase. High NADPH levels inhibit the enzyme, while the need for NADPH or ribose-5-phosphate activates flux through the pathway. Insulin upregulates the expression of glucose-6-phosphate dehydrogenase, increasing pathway activity in the fed state. The cellular need determines which products are emphasized: when NADPH is needed but ribose-5-phosphate is not, the non-oxidative phase recycles pentose phosphates back to glycolytic intermediates.
Physiological Roles
NADPH produced by the pentose phosphate pathway serves several critical functions. It provides reducing equivalents for fatty acid and steroid synthesis, maintains reduced glutathione for antioxidant defense, and supports cytochrome P450 activity in the liver. The pathway also produces ribose-5-phosphate for nucleotide and nucleic acid synthesis, which is especially important in rapidly dividing cells.
Glucose-6-Phosphate Dehydrogenase Deficiency
G6PD deficiency is the most common enzyme deficiency worldwide, affecting over 400 million people. It is an X-linked disorder that impairs NADPH production, reducing the cell’s ability to combat oxidative stress. Affected individuals experience hemolytic anemia triggered by oxidative stressors such as certain drugs (primaquine, sulfonamides), fava beans, or infections. Red blood cells are particularly vulnerable because they lack other NADPH-producing pathways.
